Did you know that accessing treatments for stage IV metastatic breast cancer (mBC) is not universal across Canada? We live in a country that promotes universal health care to all but accessing cancer treatment varies by each province.
On June 12th, the Advisory Council on the Implementation of National Pharmacare released their final report looking at the implementation of a national program to address the inequities that Canadians currently face when it comes to drug access. It outlines 60 recommendations, steps to implementation and key details on things like co-pay, budget costs, strategy for rare diseases, and impacts on patients and providers. Below, we’ve summarized these key details for you to better understand how this new plan for pharmacare would impact you and your family.
Wendie Hayes of Stoney Creek Mountain, Ontario was diagnosed in 2011 with triple negative metaplastic phyllodes breast cancer at the age of 55 after she discovered a lump in her left breast. Her cancer is a rare type, affecting less than one percent of breast cancer patients, so it took some time to get the right diagnosis.
How valuable is patient input to decision-makers and how can we work to make sure that the patient voice is really being heard? These are just some of the important questions that I and many others gathered to discuss at the annual Breast Cancer Patient Group Forum in Vienna, Austria.